Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2016 1
2018 3
2021 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
Kockerols CCB, Janssen JJWM, Blijlevens NMA, Klein SK, Van Hussen-Daenen LGM, Van Gorkom GGY, Smit WM, Van Balen P, Biemond BJ, Cruijsen MJ, Corsten MF, Te Boekhorst PAW, Koene HR, Van Sluis GL, Cornelissen JJ, Westerweel PE. Kockerols CCB, et al. Among authors: cruijsen mj. Haematologica. 2023 Jan 1;108(1):240-244. doi: 10.3324/haematol.2022.281386. Haematologica. 2023. PMID: 36073515 Free PMC article. No abstract available.
Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome.
Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijsen M, Fattizzo B, Cassin R, Fotiou D, Kastritis E, De Haas M, Oosten LEM, Frederiksen H, Patriarca A, D'Sa S, Vos JMI. Jalink M, et al. Among authors: cruijsen m. Blood. 2021 Nov 18;138(20):2002-2005. doi: 10.1182/blood.2021012039. Blood. 2021. PMID: 34293088 Free article. No abstract available.
Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma.
Maas D, Laros-van Gorkom B, Gianotten S, Cruijsen M, van Heerde W, Nijziel M. Maas D, et al. Among authors: cruijsen m. Case Rep Hematol. 2018 Jan 30;2018:7973297. doi: 10.1155/2018/7973297. eCollection 2018. Case Rep Hematol. 2018. PMID: 29651351 Free PMC article.
Low relapse risk in poor risk AML after conditioning with 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation.
Cruijsen M, Hilberink JR, van der Velden WJFM, Jansen JH, Bär B, Schaap NPM, de Haan A, Mulder AB, de Groot MR, Baron F, Vellenga E, Blijlevens NNM, Huls G. Cruijsen M, et al. Bone Marrow Transplant. 2021 Aug;56(8):1964-1970. doi: 10.1038/s41409-021-01272-3. Epub 2021 Apr 6. Bone Marrow Transplant. 2021. PMID: 33824442 Free article. Clinical Trial.
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, Duyster J, Huls G, van der Velden WJFM, Finke J, Lübbert M. Sommer S, et al. Among authors: cruijsen m. Leuk Res. 2018 Sep;72:20-26. doi: 10.1016/j.leukres.2018.07.005. Epub 2018 Jul 7. Leuk Res. 2018. PMID: 30064039 Clinical Trial.
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M, Hobo W, van der Velden WJFM, Bremmers MEJ, Woestenenk R, Bär B, Falkenburg JHF, Kester M, Schaap NPM, Jansen J, Blijlevens NNM, Dolstra H, Huls G. Cruijsen M, et al. Biol Blood Marrow Transplant. 2016 Jun;22(6):1000-1008. doi: 10.1016/j.bbmt.2016.02.003. Epub 2016 Feb 6. Biol Blood Marrow Transplant. 2016. PMID: 26860635 Free article.